Long-Term Open-Label Extension Study of Oral Levosimendan
← catalyst calendarNCT07436689 · readout ≤ 955 d
Sponsored by Tenax Therapeutics, Inc. (industry) · TENX — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
800estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-13 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Hypertension Associated With HFpEF
Intervention
- Drug: TNX-103
Primary outcome
what the primary-completion date above is the date OFThe incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs
measured From enrollment through study completion (up to 3 years)
Permalink · TENX's whole pipeline · Catalyst calendar · Every registered study · What changed